SAMPLE CHAPTER: 10. BACK TO THE FUTURE FOR PHARMA What we now know is that pharmaceutical companies took a wrong fork in the road in
Who would argue that we don’t need innovation in biopharmaceuticals? Some are even calling for disruptive innovation, to tackle the thorny issues of affordability and
PharmaFlow is pleased to announce that highly experienced EU QP David Franks has agreed to join the PharmaFlow core team of independent experts. Below is
The answer is ‘far less than you would think!’ In this STAT article Letting academic medical centers make CAR-T drugs would save billions, medical centres
PharmaFlow vows to inject transformational strategy into biopharmaceutical value-chains Industry-leading biopharmaceutical supply-chain management consultancy PharmaFlow has today repositioned itself in the market with the launch